Respiratory diseases

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology

Retrieved on: 
Tuesday, August 3, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Ondine

Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.

Key Points: 
  • Canadian medical device innovator, Ondine Biomedical, will present in vitro and in vivo results from SARS-CoV-2 programs at the European Society of Photobiology (ESP2021) in Salzburg, Austria on 31st August 2021.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many pathogens including MRSA, Candida auris and SARS-Cov-2.
  • Dr. Nicolas Loebel, Ondine Biomedicals President and Chief Technology Officer, will present the results in the Photomedicine and SARS-CoV-2/ASP-ESP Symposium.
  • Ondine Biomedical Inc. is a Canadian headquartered, medical device company led by Founder and CEO, Carolyn Cross.

Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, July 28, 2021
Health, Medical devices, Technology, Manufacturing, Other Technology, Other Manufacturing, Biotechnology, Medical specialties, Medicine, Clinical medicine, Respiratory therapy, Medical emergencies, Respiratory diseases, Canaccord Genuity, Ventilator, Hypercapnia, Genuity, Respiratory therapist, Vapotherm

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.

Encyclopedia of Respiratory Medicine. 2021 Edition - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Health, Pharmaceutical, Pulmonology, Respiratory disease, Medicine, Lung, Respiratory diseases, Respiratory therapist

The "Encyclopedia of Respiratory Medicine.

Key Points: 
  • The "Encyclopedia of Respiratory Medicine.
  • Encyclopedia of Respiratory Medicine explores the key processes of lung diseases and their diagnosis and management.
  • Written in at a time when the globe is in the grip of respiratory pandemic, lung disease has never been so prominent in the public and political conscious.
  • This new edition will provide new researchers in respiratory medicine with a solid foundation in unfamiliar topics and will update more experienced researchers seeking to step outside their core areas of research to put their work into a broader context.

Ondine Biomedical to present results on the effects of its upper airways decolonization technology for SARS-CoV-2 eradication at ICPIC 2021

Retrieved on: 
Monday, July 26, 2021
Sarbecovirus, Zoonoses, Viruses, Respiratory diseases, Severe acute respiratory syndrome

Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.

Key Points: 
  • Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.
  • The presentation will focus on results demonstrating that this patented photodisinfection therapy can rapidly destroy the RNA genome of SARS-CoV-2.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many threatening pathogens including MRSA, Candida auris, and SARS-Cov-2.
  • Ondines Steriwave photodisinfection therapy can rapidly and painlessly eradicate pathogens in the nose and upper airway, helping to eliminate a leading source of infection and transmissions.

Cell Science Systems Reports Newly Discovered Cause of Delayed Food Allergies (Sensitivities)

Retrieved on: 
Tuesday, July 13, 2021
Other Consumer, Medical devices, Infectious diseases, Women, Seniors, Genetics, Fitness & Nutrition, MEN, Other Technology, Clinical trials, Family, Biotechnology, Alternative medicine, Hardware, Consumer, Health, Science, Other Science, Technology, Research, Diabetes, Nanotechnology, Stem cells, Practice Management, Managed care, General Health, Teens, Parenting, Children, Other Health, Oncology, Medical specialties, Immunology, Clinical medicine, Food allergies, Allergology, Immune system, Respiratory diseases, Allergy, Immunoglobulin E, Wheat allergy, Allergies in cats

However, researchers from University Leipzig (Germany) and Georgetown University together with Cell Science Systems may have found the key to understanding the most difficult type of food allergies know as delayed food allergies or sensitivities.

Key Points: 
  • However, researchers from University Leipzig (Germany) and Georgetown University together with Cell Science Systems may have found the key to understanding the most difficult type of food allergies know as delayed food allergies or sensitivities.
  • Delayed food allergies or sensitivities (also referred to as non-IgE mediated food allergies) are difficult to identify because symptoms are less acute and may take hours or even days to develop.
  • Hence, there is a great need for a test that can accurately and cost-effectively identify food and food product triggers of delayed food allergies.
  • ), are responsible for delayed food allergies and release more DNA, and other associated proteins, when exposed to an ALCAT Test positive food.

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Respiratory diseases, Zoonoses, Sarbecovirus, Atypical pneumonias, Bat virome, COVID-19, Occupational safety and health, TLR2, Severe acute respiratory syndrome, COVID-19 vaccine

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.

Key Points: 
  • By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.
  • The Phase I study is a randomized, double-blind and placebo-controlled, single and multiple ascending dose study.
  • The easy-to-use nasal spray could be helpful in protecting at-risk populations, such as the elderly or patients with chronic respiratory diseases.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)

Retrieved on: 
Wednesday, July 7, 2021
Medical specialties, Medicine, Clinical medicine, Respiratory diseases, Intensive care medicine, Infant respiratory distress syndrome, Preterm birth, Syndromes, Heart failure, Acute stress disorder, Shortness of breath, Acute

WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:

Key Points: 
  • WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:
    Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis.
  • Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure.
  • Windtree has also focused on developing AEROSURF as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURFto its licensee inAsia, Lee's HK, while Windtreeevaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults.
  • Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Results of Biomarck Clinical and Preclinical Studies of BIO-11006 in ARDS to be Presented at the 2021 ARDS Drug Development Summit

Retrieved on: 
Wednesday, July 7, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Branches of biology, Clinical medicine, Intensive care medicine, Immunology, Respiratory diseases, Ards, Acute respiratory distress syndrome, Cytokine storm, Respiratory distress syndrome, Infant respiratory distress syndrome, Neutrophil

At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.

Key Points: 
  • At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.
  • Treatment with BIO-11006 prevented development of ARDS, reversed established ARDS and prevented neutrophil influx into the lungs.
  • It is hoped that these results can now be repeated in a larger clinical trial currently being planned.
  • Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm.

Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects

Retrieved on: 
Wednesday, July 7, 2021
Respiratory diseases, Medical emergencies, Medical specialties, Diving medicine, Hypercapnia, Branches of biology, Hypoventilation, Clinical medicine, Respiratory physiology, Intensive care medicine

That work used clinical utility function analysis methodology based on the original OLINVYK Phase 1 ventilatory response to hypercapnia (VRH) data.

Key Points: 
  • That work used clinical utility function analysis methodology based on the original OLINVYK Phase 1 ventilatory response to hypercapnia (VRH) data.
  • In this study, the integrated inputs of interest are analgesia (benefit) and respiratory depression (risk).
  • The study aims to recruit ~50% of subjects who are 65 years old and ~30% of subjects with a BMI > 30 kg/m2.
  • Respiratory depression will be assessed using the VRH measure, which is widely recognized as a precise method to assess respiratory physiology in humans.